In clinical samples comparing primary and recurrent GBM, varying expression levels of targets such as ALK, PDGFRβ, PDGFRA, MET, FGFR1, FGFR2, and FGFR3 have been observed, indicating significant heterogeneity throughout the disease’s progression. This evidence concerns the gene FGFR1 and glioblastoma.